Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | SHBG | P04278 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 3/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5550789 | 0.90 | MAPT (0.53) | MAPTLMNASERPINA6CYP3A4MEN1 | |
| SCHEMBL11517687 | 0.86 | MAPT (0.49) | MAPTLMNASERPINA6CYP3A4MEN1 | |
| SCHEMBL13804528 | 0.84 | MAPT (0.71) | MAPTLMNASERPINA6CYP3A4MEN1 | |
| SCHEMBL17302789 | 0.84 | MAPT (0.71) | MAPTLMNASERPINA6CYP3A4MEN1 | |
| SCHEMBL2930366 | 0.84 | MAPT (0.71) | MAPTLMNASERPINA6CYP3A4MEN1 | |
| SCHEMBL13177160 | 0.84 | MAPT (0.71) | MAPTLMNASERPINA6CYP3A4MEN1 | |
| SCHEMBL16741272 | 0.84 | SERPINA6 (0.71) | MAPTLMNASERPINA6CYP3A4MEN1 | |
| SCHEMBL5551986 | 0.83 | MAPT (0.59) | MAPTLMNASERPINA6CYP3A4MEN1 | |
| SCHEMBL16188590 | 0.82 | SHBG (0.69) | MAPTLMNASERPINA6CYP3A4MAPK1 | |
| SCHEMBL7615553 | 0.82 | SHBG (0.69) | MAPTLMNASERPINA6CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912737-B2 | 19-nor neuroactive steroids and methods of use thereof | Sage Therpeutics, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912737-B2 | 19-nor neuroactive steroids and methods of use thereof | Sage Therpeutics, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11241446-B2 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210139531-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210061849-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-10822370-B2 | 19-nor neuroactive steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200165291-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200155576-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-10342810-B2 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190112331-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2019-04-18 | — | — | US | disclosed |
| US-9512165-B2 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512165-B2 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160108080-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-04-21 | — | — | US | disclosed |
| US-20160108080-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-04-21 | — | — | US | disclosed |
| US-20160068563-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160068563-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
| WO-2015180679-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| WO-2014169836-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2014-10-23 | — | — | WO | disclosed |
| EP-1128810-A1 | DRUG DELIVERY DEVICE, ESPECIALLY FOR THE DELIVERY OF ANDROGENS | LEIRAS OY (FI) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000028967-A1 | DRUG DELIVERY DEVICE, ESPECIALLY FOR THE DELIVERY OF ANDROGENS | LEIRAS OY (FI) | 2000-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112331-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | NR3C2, HSD3B1, HSD3B2 | MAPT 1029/4885LMNA 2913/4885SERPINA6 407/4885 |
| US-20160108080-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | NR3C2, CYP11B1, NR3C1 | MAPT 1908/4885LMNA 2718/4885SERPINA6 931/4885 |
| US-20200165291-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CNR1, NR3C2, CNR2 | MAPT 1381/4885LMNA 3434/4885SERPINA6 560/4885 |
| US-11912737-B2 | 19-nor neuroactive steroids and methods of use thereof | NR3C2, HSD3B1, HSD3B2 | MAPT 1029/4885LMNA 2913/4885SERPINA6 407/4885 |
| US-20200155576-A1 | 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF | NR3C2, NR3C1, CYP11B1 | MAPT 1772/4885LMNA 2657/4885SERPINA6 1023/4885 |
| US-10342810-B2 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | NR3C2, NR3C1, CYP11B1 | MAPT 1772/4885LMNA 2657/4885SERPINA6 1023/4885 |
| US-11241446-B2 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | NR3C2, NR3C1, CYP11B1 | MAPT 1772/4885LMNA 2657/4885SERPINA6 1023/4885 |
| US-20210139531-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | NR3C2, HSD3B1, HSD3B2 | MAPT 1029/4885LMNA 2913/4885SERPINA6 407/4885 |
| US-20160068563-A1 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | NR3C2, HSD3B1, HSD3B2 | MAPT 1029/4885LMNA 2913/4885SERPINA6 407/4885 |
| US-10822370-B2 | 19-nor neuroactive steroids and methods of use thereof | NR3C2, HSD3B1, HSD3B2 | MAPT 1029/4885LMNA 2913/4885SERPINA6 407/4885 |
| US-20210061849-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CNR1, NR3C2, CNR2 | MAPT 1381/4885LMNA 3434/4885SERPINA6 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.